Wnt3 gene expression promotes tumor progression in non-small cell lung cancer.

[1]  D. Rao,et al.  siRNA vs. shRNA: similarities and differences. , 2009, Advanced drug delivery reviews.

[2]  Takashi Nakashima,et al.  Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. , 2008, European journal of cancer.

[3]  P. Hainaut,et al.  Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma , 2008, British Journal of Cancer.

[4]  E. Yu,et al.  Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. , 2008, Journal of hepatology.

[5]  R. Haba,et al.  The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers , 2008, British Journal of Cancer.

[6]  Shubiao Zhang,et al.  Lipoplex morphologies and their influences on transfection efficiency in gene delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[7]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  M. Ueno,et al.  Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor--an expression in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Nguyên,et al.  Differential roles for the coactivators CBP and p300 on TCF/β-catenin-mediated survivin gene expression , 2005, Oncogene.

[10]  R. Haba,et al.  Clinical application of biological markers for treatments of resectable non-small-cell lung cancers , 2005, British Journal of Cancer.

[11]  T. Timme,et al.  Combined c‐Myc and caveolin‐1 expression in human prostate carcinoma predicts prostate carcinoma progression , 2005, Cancer.

[12]  T. Yoshikawa,et al.  Expression of survivin mRNA associates with apoptosis, proliferation and histologically aggressive features in hepatocellular carcinoma. , 2004, Oncology reports.

[13]  Matthew Meyerson,et al.  Somatic alterations in the human cancer genome. , 2004, Cancer cell.

[14]  K. Imai,et al.  Activation of WNT Family Expression and Signaling in Squamous Cell Carcinomas of the Oral Cavity , 2004, Journal of dental research.

[15]  H. Clevers,et al.  Survivin and molecular pathogenesis of colorectal cancer , 2003, The Lancet.

[16]  Yasuo Watanabe,et al.  Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. , 2002, International journal of oncology.

[17]  Masaru Katoh.  WNT3-WNT14B and WNT3A-WNT14 gene clusters (Review). , 2002, International journal of molecular medicine.

[18]  G. Salvesen,et al.  Apoptosis: IAP proteins: blocking the road to death's door , 2002, Nature Reviews Molecular Cell Biology.

[19]  M. Katoh.  Regulation of WNT3 and WNT3A mRNAs in human cancer cell lines NT2, MCF-7, and MKN45. , 2002, International journal of oncology.

[20]  M. Katoh,et al.  Molecular cloning and characterization of human WNT3. , 2001, International journal of oncology.

[21]  D. Chung,et al.  Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. , 2001, Cancer research.

[22]  M. Hirai,et al.  Molecular cloning and characterization of WNT3A and WNT14 clustered in human chromosome 1q42 region. , 2001, Biochemical and biophysical research communications.

[23]  W. Earnshaw,et al.  Chromosomal passengers and the (aurora) ABCs of mitosis. , 2001, Trends in cell biology.

[24]  M. Volm,et al.  Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer. , 2000, Oncology reports.

[25]  Randall T Moon,et al.  Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca2+ pathways , 1999, Oncogene.

[26]  E Springer,et al.  Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. , 1999, Cancer research.

[27]  K. Zeller,et al.  Function of the c-Myc oncogenic transcription factor. , 1999, Experimental cell research.

[28]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[29]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[30]  D. Altieri,et al.  Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. , 1998, Cancer research.

[31]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[32]  G. Sirugo,et al.  Induction of Apoptosis and Inhibition of Cell Proliferation bysurvivin Gene Targeting* , 1998, The Journal of Biological Chemistry.

[33]  D. Altieri,et al.  Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. , 1998, Cancer research.

[34]  T. Dale,et al.  Signal transduction by the Wnt family of ligands. , 1998, The Biochemical journal.

[35]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[36]  K. Kinzler,et al.  Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma , 1997, Science.

[37]  A. Brown,et al.  Induction of kidney epithelial morphogenesis by cells expressing Wnt-1. , 1994, Developmental biology.